| human | Q5 |
| P496 | ORCID iD | 0000-0002-8397-100X |
| P734 | family name | Munshi | Q36986483 |
| Munshi | Q36986483 | ||
| Munshi | Q36986483 | ||
| P735 | given name | Nikhil | Q1990189 |
| Nikhil | Q1990189 | ||
| P106 | occupation | researcher | Q1650915 |
| Q44117650 | 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells |
| Q41009823 | A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. |
| Q61905635 | A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis |
| Q37709866 | A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications |
| Q33944281 | A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma |
| Q88611111 | A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma |
| Q33412684 | A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma |
| Q33395607 | A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma |
| Q33834752 | A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells |
| Q37035836 | APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. |
| Q44098361 | Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications |
| Q64931827 | Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. |
| Q36835070 | Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu |
| Q40380103 | Antimyeloma activity of heat shock protein-90 inhibition. |
| Q39827794 | Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. |
| Q40606773 | Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma |
| Q39966416 | Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo |
| Q44010411 | Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications |
| Q24670297 | Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo |
| Q37201984 | Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications |
| Q34523149 | Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications |
| Q88141406 | Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy |
| Q24598483 | Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma |
| Q37202761 | Bortezomib in the front-line treatment of multiple myeloma |
| Q34418462 | Bortezomib in the management of multiple myeloma. |
| Q37291635 | Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells |
| Q36206430 | Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma |
| Q30487339 | CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. |
| Q79323648 | Can thalidomide improve outcome in patients with multiple myeloma? |
| Q38805629 | Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. |
| Q35125918 | Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients |
| Q34648345 | Classify hyperdiploidy status of multiple myeloma patients using gene expression profiles |
| Q44045389 | Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. |
| Q35859205 | Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells |
| Q36407209 | Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma |
| Q40524119 | Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma |
| Q28383385 | Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function |
| Q33620440 | Conflicts of interest, authorship, and disclosures in industry-related scientific publications |
| Q37835572 | Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. |
| Q37835574 | Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. |
| Q37835571 | Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. |
| Q40720850 | Cytokines modulate telomerase activity in a human multiple myeloma cell line. |
| Q64112513 | Deciphering the chronology of copy number alterations in Multiple Myeloma |
| Q41702673 | Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations |
| Q34508343 | Differential and limited expression of mutant alleles in multiple myeloma |
| Q24673367 | Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis |
| Q80395737 | Does maintenance therapy with thalidomide benefit patients with multiple myeloma? |
| Q38361677 | Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? |
| Q40626130 | Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells |
| Q30431530 | Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma |
| Q37457302 | Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib |
| Q36289316 | Emerging trends in the clinical use of bortezomib in multiple myeloma |
| Q33967101 | Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study |
| Q36651351 | Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells |
| Q40314855 | FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma |
| Q89228016 | Functional cargo delivery into mouse and human fibroblasts using a versatile microfluidic device |
| Q30490975 | Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. |
| Q95648939 | Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression |
| Q88636696 | Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing |
| Q24670205 | Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor |
| Q37528285 | Heterogeneity of genomic evolution and mutational profiles in multiple myeloma |
| Q50533942 | Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. |
| Q40402220 | Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma |
| Q38359832 | Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays |
| Q40749337 | Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays |
| Q58792995 | Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma |
| Q44598249 | Immunomodulatory drug costimulates T cells via the B7-CD28 pathway |
| Q40339607 | Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications |
| Q34369823 | Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma |
| Q33902726 | In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells |
| Q36902187 | In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. |
| Q40087316 | Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells |
| Q58554182 | Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia |
| Q40629582 | Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. |
| Q36902184 | Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib |
| Q38832525 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma |
| Q36929923 | International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease |
| Q37098847 | Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity |
| Q37986287 | Latest advances and current challenges in the treatment of multiple myeloma |
| Q38874291 | Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma |
| Q33973877 | Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy |
| Q46549116 | Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma |
| Q38852886 | Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. |
| Q33389111 | Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma |
| Q38611142 | Logic programming reveals alteration of key transcription factors in multiple myeloma |
| Q88636701 | Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma |
| Q37925775 | MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. |
| Q79188378 | MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo |
| Q37978343 | Management of myeloma-associated renal dysfunction in the era of novel therapies |
| Q85048468 | Management of relapsed and relapsed/refractory multiple myeloma |
| Q37898151 | Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings |
| Q40566183 | Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications |
| Q57151125 | Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma |
| Q37533983 | Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens |
| Q33702365 | Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications |
| Q40453614 | Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. |
| Q44189620 | Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. |
| Q44280918 | Molecular sequelae of histone deacetylase inhibition in human malignant B cells |
| Q34393832 | Molecular sequelae of proteasome inhibition in human multiple myeloma cells |
| Q33386405 | Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma |
| Q36839270 | Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment |
| Q34521393 | NF-kappa B as a therapeutic target in multiple myeloma |
| Q44484456 | NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma |
| Q36865500 | New drugs for myeloma |
| Q33621610 | Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. |
| Q34996147 | Novel biologically based therapies for multiple myeloma |
| Q37624943 | Novel therapies in the treatment of multiple myeloma |
| Q78762135 | Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein |
| Q33414827 | Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide |
| Q64086734 | PAN-INTACT enables direct isolation of lineage-specific nuclei from fibrous tissues |
| Q34124937 | PI3K/p110{delta} is a novel therapeutic target in multiple myeloma |
| Q36170645 | Pathological crystallization of human immunoglobulins |
| Q92036531 | Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study |
| Q44442859 | Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial |
| Q40328451 | Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells |
| Q34008578 | Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib |
| Q33941043 | Phase transitions in human IgG solutions |
| Q36328301 | Phenotypically silent Cre recombination within the postnatal ventricular conduction system |
| Q24643402 | Prognostic significance of copy-number alterations in multiple myeloma |
| Q88470620 | Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 |
| Q40464000 | Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. |
| Q44662272 | Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma |
| Q34526773 | Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model |
| Q34398382 | Pyk2 promotes tumor progression in multiple myeloma |
| Q38059720 | Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop |
| Q40259847 | Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment |
| Q35220653 | Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience |
| Q92372452 | Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy |
| Q37280739 | Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy |
| Q43046672 | Tailoring treatment for multiple myeloma patients with relapsed and refractory disease |
| Q40017245 | Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment |
| Q35989478 | Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis |
| Q81248007 | Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma |
| Q36352540 | Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. |
| Q44951900 | Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells |
| Q35616060 | Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM) |
| Q36506849 | The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival |
| Q35700723 | The Medical Research Council Myeloma IX trial: the impact on treatment paradigms |
| Q38852406 | The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. |
| Q53947641 | The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. |
| Q40569001 | The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance |
| Q91157806 | The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease |
| Q39840677 | The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo |
| Q83387231 | The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib |
| Q44211035 | The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications |
| Q36998198 | The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies |
| Q36501937 | The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions |
| Q35006859 | The shaping and functional consequences of the dosage effect landscape in multiple myeloma |
| Q42044723 | The treatment of multiple myeloma patients not eligible for asct |
| Q37007400 | The treatment of relapsed and refractory multiple myeloma |
| Q44123720 | The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment |
| Q34106817 | Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus |
| Q35116846 | Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. |
| Q37207049 | Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. |
| Q36761567 | Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans |
| Q33732491 | Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma |
| Q37128664 | Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients |
| Q47861350 | Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma |
| Q33394281 | Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study |
| Q40504955 | p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells |
| Q40382947 | p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma |
| Q93170062 | pouC Regulates Expression of bmp4 During Atrioventricular Canal Formation in Zebrafish |
Search more.